Pharmacological treatment of cancer pain: Alternative routes of opioid administration

Tumori

Volumn 84, Issue 3, 1998, Pages 289-300

  Ripamonti, Carla ^a   Zecca, Ernesto ^a   De Conno, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alternative routes; Cancer pain; Opioids

Indexed keywords

CYCLIZINE; DEXAMETHASONE; HALOPERIDOL; HYDROMORPHONE; HYDROXYZINE; KETAMINE; KETOROLAC; LORAZEPAM; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; OCTREOTIDE; OPIATE; PETHIDINE; PHENOBARBITAL; SCOPOLAMINE;

ADVANCED CANCER; CANCER PAIN; CLINICAL PRACTICE; DRUG INDICATION; INTRASPINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT CONTROLLED ANALGESIA; PRACTICE GUIDELINE; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031809761     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400302     Document Type: Review

References (97)

1. Arner S., Rawal N., Gustafsson L.: Chemical experience of long-term treatment with epidural and intrathecal infusional therapies for intractable pain: patient management guidelines. J. Pain Symp. Manag., 8: 36-46, 1993.
2. Arner S., Arner B.: Differential effects of epidural morphine in the treatment of cancer-related pain. Acta Anaesthesiol. Scand., 29: 32-36, 1985.
3. Ballard B.E.: Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. Pharm. Sci., 57: 357-359, 1968.
4. Baumann T.J., Batenhorst R.L., Graves D.A.: Patient-controlled analgesia in the terminally ill cancer patient. Drug Intell. Clin. Pharm., 20: 297-301, 1986.
5. Bonica J.J.: Cancer pain. In: The Management of Pain. Bonica J.J. (Ed.), 2nd edn., Vol. 1, pp. 400-460, Lea & Febiger, Philadelphia, 1990.
6. Breda M., Bianchi M., Ripamonti C., Zecca E., Ventafridda V., Panerai A.E.: Plasma morphine and morphine 6-glucuronide patterns in cancer patients after oral, subcutaneous, sublabial and rectal short-term administration. J. Clin. Pharm. Res., 11: 93-97, 1991.
7. Bruera E., MacMillan K., Hanson J.: Palliative care in a cancer center: Results in 1984 versus 1987. J. Pain Symp. Manag., 5: 1-5, 1990.
8. Bruera E., Ripamonti C.: Alternative routes of administration of opioids for the management of cancer pain . In: Cancer Pain, Patt (Ed.), pp. 161-184, Lippincott, Philadelphia, 1993.
9. Bruera E., Faisinger R., Spachynski K., Babul N., Harsanyi Z., Darke A.: Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation. J. Clin. Oncol., 13: 1520-1527, 1995.
10. Bruera E., Watanabe S., Faisinger R., Spachynski K., Suarez-Almazor M., Inturrisi C.: Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain, 62: 141-146, 1995.
11. Bruera E., Brenneis C., Michaud M., Bacovsky R., Chadwick S., Emeno A., MacDonald N.: Use of the subcutaneous route for administration of narcotics in patients with cancer pain. Cancer, 62: 407-411, 1988.
12. Bruera E., Faisinger R., Moore M., Thibault R., Spoldi E., Ventafridda V.: Local toxicity with subcutaneous methadone. Experience of two centers. Pain, 45: 141-143, 1991.
13. Bruera E., Brenneis C., Michaud M., MacMillan K., Hanson J., MacDonald R.N.: Patient-controlled subcutaneous hydromorphone vs continuous subcutaneous infusion for the treatment of cancer pain. J. Natl. Cancer Inst., 80: 1152-1154, 1988.
14. Bruera E., Velasco-Leiva A., Spachynski K., Faisinger R., Miller M. J., MacEachern T.: Use of the Edmonton injector for parenteral opioid management of cancer pain: a study of 100 consecutive patients. J. Pain Symp. Manag., 8: 525-528, 1993.
15. Caplan R.A., Ready L.B., Oden R.V., Matsen F.A., Nessley M.L., Ohlsson G.L.: Transdermal fentanyl for postoperative pain management. A double-blind-placebo study. J.A.M.A., 261: 1036-1039, 1989.
16. Chandler S.W., Trissel L.A., Weinstein S.M.: Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: initial safety screening for compatibility. J. Pain Symp. Manag., 12: 168-171, 1996.
17. Cherny N.J., Chang V., Frager G., Ingham J.M., Tiseo P.J., Popp B., Portenoy R., Foley K.M.: Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer, 76: 1283-1293, 1995.
18. Cherry A.D., Gourlay G.K.: The spinal administration of opioids in the treatment of acute and chronic pain: bolus doses, continuous infusion, intraventricular administration and implanted drug delivery systems. Pall. Med., 1: 89-106, 1987.
19. Citron M.L., Johnson-Early A., Boyer M., Krasnow S.H., Hood M., Cohen M.H.: Patient-controlled analgesia for severe cancer pain. Arch. Intern. Med., 146: 734-736, 1986.
20. Citron M.L., Johnson-Early A., Fassieck B.E.: Safety and efficacy of continuous intravenous morphine for severe cancer pain. Am. J. Med., 17: 199-204, 1984.
21. Cole L., Hanning C.D.: Review of the rectal use of opioids. J. Pain Symp. Manag., 5: 118-126, 1990.
22. Cousin M.J., Plummer J.L.: Spinal opioids in acute and chronic pain. In: Advances in Pain Research and Therapy. Max M.B., Portenoy R.L., Laska, E. (Eds.), vol. 18, pp. 457-480, Raven Press, New York, 1991.
23. Coyle N., Adelhart J., Foley K.M., Portenoy R.K.: Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J. Pain Symp. Manag., 5: 83-93, 1990.
24. Coyle N., Mauskop A., Maggard J., Foley K.: Continuous subcutaneous infusion of opiates in cancer patients with pain. Oncol. Nursing Forum, 13: 53-57, 1986.
25. Daut R.L., Cleeland C.S.: The prevalence and severity of pain in cancer. Cancer, 50: 1913-1918, 1982.
26. De Boer A.G., De Leede L.G., Breimer D.D.: Drug absorption by sublingual and rectal route. Br. J. Anaesth., 56: 69-82, 1984.
27. De Conno F., Groff L., Brunelli C., Zecca E., Ventafridda V., Ripamonti C.: Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J. Clin. Oncol., 14: 2836-2842, 1996.
28. De Conno F., Ripamonti C., Saita L., MacEachern T., Hanson J., Bruera E.: Role of rectal route in treating cancer pain: a randomized cross-over clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J. Clin. Oncol., 13: 1004-1008, 1995.
29. Devulder J.: PCA and cancer pain. Acta Anaesthesiol. Belg., 43: 53-56, 1992.
30. Dickenson A.H., Sullivan A.F., McQuay H.S.: Intrathecal etorphine, fentanyl and buprenorphine on spinal nociceptive neurones in the rat. Pain, 42: 227-234, 1990.
31. Donner B., Zenz M., Tryba M., Strumpf M.: Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain, 64: 527-534, 1996.
32. Drexel H., Dzien A., Spiegel R.W., Lang A.H., Breier C., Abbrederis K., Patsch J.R., Braunsteiner H.: Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain, 36: 169-176, 1989.
33. Eimeral D., Magora F., Shir Y.: Patient-controlled analgesia with epidural methadone by means of an external infusion pump Schmertz-pai-Doleur, 4: 156, 1986.
34. Evans E.F., Proctor J.D., Fratkin M.J., Velandia J., Wasserman A.J.: Blood flow in muscle groups and drug absorption. Clin. Pharmacol. Ther., 17: 44-47, 1975.
35. Foley K.: The treatment of cancer pain. N. Engl. J. Med., 313: 84-94, 1985.
36. Goudie T., Allan M., Lansdale M.: Continuous subcutaneous infusion of morphine for postoperative pain relief. Anesth. Analg., 40: 1086-1092, 1985.
37. Gourlay G.K., Kawalski S.R., Plummer J.L.: The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain, 40: 21-28, 1990.
38. Guy R.H., Hadgraft J.: Transdermal drug delivery: the ground rules are emerging. Pharmacy Int., 6: 112-116, 1985.
39. Hanks G.W., De Conno F., Ripamonti C., Hanna M., McQuay H.J., Mercadante S., Meynadier J., Polain P., Roca j casa J., Sawe J., Twycross R.G., Vainio A., Zech D.: Morphine in cancer pain: modes of administration. BMJ, 312: 823-826, 1996.
40. Hardy P.A., Wells J.C.: Patient-controlled intrathecal morphine for cancer pain: a method used to assess morphine requirements and bolus doses. Clin. J. Pain, 6: 57-59, 1990.
41. Herbst L.H., Strause L.G.: Transdermal fentanyl use in hospice-home care patients with chronic cancer pain. J. Pain Symp. Manag., 7 (suppl.): S 54-57, 1992.
42. Hill H.F., Chapman C.R., Kornell J., Sullivan K.M., Saeger L.C., Benedetti C.: Self-administration of morphine in bone marrow transplant patients reduces drug requirements. Pain, 40: 121-129, 1990.
43. Hill H.F., Chapman C.R.: Patient-controlled analgesia versus continuous infusion morphine in cancer patients: lack of tolerance development. Pain, 4 (suppl): S 342, 1988.
44. Hill H.F., Mackie A.M., Coda B.A., Iverson K., Chapman C.R.: PCA administration: a comparison of steady-state morphine infusions with bolus dose. Cancer, 67: 873-882, 1991.
45. Hill H.F., Mackie A.M., Coda B.A.: Evaluation of the accuracy of a pharmacokinetically based patient-controlled analgesia system. Eur. J. Clin. Pharmacol., 43: 67-75, 1992.
46. Hill H.F., Coda B.A., Mackie A.M., Iverson K.: Patient-controlled analgesic infusions: alfentanil versus morphine. Pain, 49: 301-310, 1992.
47. Hill H.F., Adam M.M., Coda B.A.: Patient-controlled analgesic infusion. In: Advances in Pain Research and Therapy, Max M., Portenoy R., Lask E. (Eds.), vol. 18, pp. 507-53, Raven Press, New York, 1991.
48. Hogan Q., Haddox J.D., Abram S., Weissman D., Taylor M.L., Janjan N.: Epidural opiates and local anesthetics for the management of cancer pain. Pain, 46: 271-279, 1984.
49. Hollinshead W.H.: The head and neck. In: Anatomy for Surgeons, vol. 1, p. 426, Harper & Row, New York, 1968.
50. Hojsted J., Rubeck K., Peterson H.: Comparative bioavailability of a morphine suppository given rectally and in a colostomy. Eur. J. Clin. Pharmacol., 39: 49-50, 1990.
51. Hutchinson H.T., Leedham G.D., Knight A.M.: Continuous subcutaneous analgesics and antiemetics in domiciliary terminal care. Lancet, 1: 1279, 1981.
52. Jacobson L., Chabal C., Brody M.C., Ward R.J., Wasse L.: Intrathecal methadone: a dose-response study and comparison with intrathecal morphine 0.5 mg. Pain, 41:147-148 1990.
53. Kaiko R.F.: Controversy in the management of chronic cancer pain: therapeutic equivalents of IM and PO morphine. J. Pain Symp. Manag., 1: 42-46, 1986.
54. Kalso E., Heiskanen T., Rantio M., Rosenberg P.H., Vainio A.: Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain, 67: 443-449, 1996.
55. Kerr I.G., Sone M., De Angelis C., Iscoe N., MacKenzie R., Schueller T.: Continuous narcotic infusion with PCA for chronic cancer pain in outpatients. Ann. Intern. Med., 108: 554-557, 1988.
56. Krames E.: Intrathecal infusional therapies for intractable pain: patient management guidelines. J. Pain Symp. Manag., 8: 36-46, 1993.
57. Korte W., de Stoutz N., Morant R.: Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short and long-term experiences in a prospective study of 39 patients. J. Pain Symp. Manag., 11: 139-146, 1996.
58. Lawrie S.C., Forbes D.W., Akhtar T.M., Morton N.S.: Patient-controlled analgesia in children. Anaesthesia, 45: 1074-1076, 1990.
59. Leow K.P., Cramond T., Smith M.T.: Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth. Analg., 80: 296-302, 1995.
60. Levy M.H., Rosen S.M., Kedziera P.: Transdermal fentanyl: seeding trial in patients with chronic pain. J. Pain Symp. Manag.: 7: S 48-50, 1992.
61. Mache A.U., Coda B.C., Hill H.F.: Adolescent use patient-controlled analgesia effectively for relief from prolonged oropharyngeal mucositis pain. Pain, 46: 265, 1991.
62. McQuay H.J., Sullivan A.F., Smallman K., Dickhenson A.H.: Intrathecal opioids, potency and lipophilicity. Pain, 36:11-15, 1989.
63. Meuret G., Jocham H.: Patient-controlled analgesia in the domiciliary care of tumor patients. Cancer Treat. Rev., 22: 137-140, 1996.
64. Michaels A.S., Chandrasckaron S.K., Shaw J.E.: Drug permeation through human skin: theory and vitro experimental measurement. Am. Inst. Chem. Engineers, 21: 985-96, 1975.
65. Miser A.W., Narang P.K., Dothage J.A., Young R.C., Sindelar W., Miser J.S.: Transdermal fentanyl for pain control in patients with cancer. Pain, 37:15-21, 1989.
66. Moulin D.E., Kreeft J.H., Parsons N.M.: Comparison of continuous subcutaneous and intravenous hydromorphone for management of cancer pain. Lancet, 337: 465-468, 1991.
67. Nahata M., Miser A., Reuning R.: Analgesic plasma concentrations of morphine in children with terminal malignancy receiving a continuous subcutaneous infusion of morphine to control severe pain. Pain, 18: 109, 1984.
68. Oliver D.J.: The use of the syringe driver in terminal care. Br. J. Clin. Pharmacol., 20: 515-516, 1985.
69. Ohlsson L., Rydberg T., Eden T., Persson Y., Thulin L.: Cancer pain relief by continuous administration of epidural morphine in a hospital setting and at home. Pain, 48: 349-354, 1992.
70. Osborne R., Joel S., Trew D.: Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine 6-glucuronide. Clin. Pharmacol. Ther., 47: 12-19, 1990.
71. Owen H., Mather L.E., Rowley K.: The development and clinical use of patient-controlled analgesia. Anaesth. Intensive Care, 16: 437-439, 1988.
72. Pannuti F., Rossi A.P., Iafelice G.: Control of chronic pain in very advanced cancer patients with morphine hydrochloride administred by oral, rectal and sublingual routes. Clinical report and preliminary results on morphine pharmacokinetics. Pharmacol. Res. Commun., 14: 369-380, 1982.
73. Plezia P.M., Dramer T.H., Linford J., Hamcroff S.R.: Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy, 9: 2-9, 1989.
74. Portenoy R.K., Moulin D.E., Rogers A., Inturrisi C.E., Foley K.M.: IV infusion of opioids for cancer pain: clinical review and guidelines for use. Cancer Treat. Report, 70: 575-81, 1986.
75. Portenoy R.K., Southam M.A., Gupta S.K., Lapin J., Layman M., Inturrisi C.E., Foley K.M.: Transdermal fentanyl for cancer pain. Anesthesiology, 78: 36-43, 1993.
76. Rawal N.: Indication for the use of intraspinal opioids. In: Spinal Narcotics, Rawal N., Coombs D.W. (Eds.), pp. 43-61, Kluwer, Boston, 1990.
77. Ripamonti C., Bruera E.: Rectal, buccal and sublingual narcotics for the management of cancer pain. J. Pall. Care, 7: 30-35, 1991.
78. Ripamonti C., Bruera E.: Transdermal and inhalatory routes of opioid administration: the potential application in cancer pain. Pall. Med., 6: 98-104, 1992.
79. Ripamonti C., Zecca E., Brunelli C., Rizzio E., Saita L., Lodi F., De Conno F.: Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann. Oncol., 6: 841-843, 1995.
80. Ripamonti C., Bruera E.: Current status of patient-controlled analgesia in cancer patients. Oncology, 11: 373-384, 1997.
81. Shir Y., Yehuda DB., Palliact A.: Prolonged continuous epidural methadone analgesic in the treatment of back and pelvic pain due to multiple myeloma. Pain Clin., 1: 255-259, 1987.
82. Shouloung L., Janlong W., Rongzeng W.: Clinical application of patient-controlled apparatus for ventricular administration of morphine in intractable pain: report of 28 cases. Neurosurgery, 29: 73-75, 1991.
83. Simmonds M.A., Richenbachern J.: Transdermal fentanyl: a long-term analgesic study. J. Pain Symp. Manag., 7: 536-539, 1992.
84. Sjogren P., Banning A.: Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain, 39:5-11, 1989.
85. Storey P., Hill H.H., St Louis R., Tarver E.E.: Subcutaneous infusions for control of cancer symptoms. J. Pain Symp. Manag., 5: 33-41, 1990.
86. Swanson G., Smith J., Bulich R., New P., Shiffman R.: Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J. Clin. Oncol., 7: 1903-1908, 1989.
87. Tang A.H., Schoenfeld M.J.: Comparison of subcutaneous and intraspinal subarachnoid injections of morphine and naloxone on analgesic tests in the rat. Eur. J. Pharmacol., 52: 215-223, 1978.
88. TTS Fentanyl Multicentre Study Group: Transdermal fentanyl in cancer pain. J. Drug Dev., 6: 93-97, 1994.
89. Urquhart M.L., Klapp K., White P.F.: Intravenous versus subcutaneous hydromorphone for patient-controlled analgesia. Anaesthesia, 7: A231, 1987.
90. Vainio A., Tigerstedt I.: Opioid treatment for radiating cancer pain: oral administration vs epidural techniques. Acta Anaesthesiol. Scand., 32: 179-180, 1988.
91. Varvel J.R., Shafer S.L., Hwang S.S., Coen P.A., Stanski D.R.: The absorption characteristics of transdermally administered fentanyl. Anesthesiology, 70: 928-934, 1989.
92. Ventafridda V., Spoldi E., Caraceni A., Tamburini M., De Conno F.: The importance of subcutaneous morphine administration for cancer control. Pain Clin., 1: 47-55, 1986.
93. Waldmann C., Eason J., Rambohul E.: Serum morphine levels: a comparison between continuous subcutaneous and intravenous infusion in postoperative patients. Anaest. Analg., 39: 768-770, 1984.
94. Weinberg D.S., Inturrisi C.E., Reidewberg B.: Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther., 44: 335-342, 1988.
95. World Health Organization: Cancer Pain Relief. WHO, Geneva, 1986.
96. World Health Organization: Cancer Pain Relief. WHO, Geneva, 1996.
97. Zech D.F., Grond S.U., Lynch J., Dauer H.G., Stollenwerk B., Lehmann K.: Transdermal fentanyl and initial dose-findings with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain, 50: 293-301, 1992.